ZBIO
HEALTHCAREZenas BioPharma, Inc. Common Stock
AI Insight
What's Moving ZBIO Today?
No stock-specific AI insight has been generated for ZBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.91$44.60
$20.21
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-9.10
Dividend Yield—
Dividend / Share—
ROE-137.1%
Profit Margin—
Debt / Equity—
Trading
Volume513K
Avg Volume (10D)—
Shares Outstanding63.1M
ZBIO News
27 articles- Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.Motley Fool·Jun 21, 2026
- Zenas BioPharma (ZBIO) director awarded 500K stock options at $18.71Stock Titan·Jun 18, 2026
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 17, 2026
- Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitYahoo Finance·Jun 11, 2026
- Zenas BioPharma reports positive phase 3 trial results for obexelimab By Investing.comInvesting.com Australia·Jun 3, 2026
- Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic SignalsYahoo Finance·Jun 3, 2026
- Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of MedicineYahoo Finance·Jun 2, 2026
- A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price WeaknessYahoo Finance·Jun 1, 2026
- Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RDYahoo Finance·May 28, 2026
- Insiders Buy the Dip in These 2 Crushed Stocks With Strong Buy RatingsYahoo Finance·May 21, 2026
- Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS SegmentTipRanks·May 19, 2026
- Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressYahoo Finance·May 19, 2026
- Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net LossYahoo Finance·May 13, 2026
- Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF InhibitorYahoo Finance·May 13, 2026
- Tomas Kiselak resigns from Zenas BioPharma board after term expirationTradingView·May 13, 2026
- Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, vs. FactSet Est of $1.47 Lossmarketscreener.com·May 13, 2026
- Zenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory SubmissionsQuiver Quantitative·May 13, 2026
- Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 13, 2026
- IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi LeadingYahoo Finance·May 7, 2026
- Insiders Are Scooping Up These 2 ‘Strong Buy’ StocksYahoo Finance·Apr 8, 2026
- InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock UpsideBenzinga·Mar 30, 2026
- Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution RiskYahoo Finance·Mar 29, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Mar 27, 2026
- Sector Update: Health Care Stocks Retreat Friday AfternoonYahoo Finance·Mar 27, 2026
- Wall Street Set to Open Lower in Friday Trading; Investors Not Assuaged by US Deadline Extension for Iran to Open Strait of HormuzYahoo Finance·Mar 27, 2026
- Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 MillionGlobeNewswire Inc.·Mar 27, 2026
- Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common StockYahoo Finance·Mar 26, 2026
All 27 articles loaded
Price Data
Open$20.54
Previous Close$20.80
Day High$21.25
Day Low$20.18
52 Week High$44.60
52 Week Low$8.91
52-Week Range
$8.91$44.60
$20.21
Fundamentals
Market Cap$1.2B
P/E Ratio—
EPS$-9.10
Dividend Yield—
Dividend / Share—
ROE-137.1%
Profit Margin—
Debt / Equity—
Trading
Volume513K
Avg Volume (10D)—
Shares Outstanding63.1M
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—